Navigation Links
AngioGenex Presents Data on its Id Targeted Anti-Angiogenesis Inhibitors at Two Scientific Conferences
Date:2/3/2009

New York, Feb. 3 /PRNewswire-FirstCall/ -- AngioGenex Inc. (OTC Bulletin Board: AGGX.OB) is a New York-based biotechnology company that is pioneering the targeting of Id genes and proteins for the discovery and development of anti-angiogenic drugs to treat cancer. Today the Company announced that it presented animal data at two recent scientific meetings that demonstrate the ability of its lead small molecule candidate drug AGX51 to mitigate tumor formation and metastases.

Dr. Robert Benezra, the scientific founder of AngioGenex and Head of the Company's Scientific Advisory Board presented at the Keystone Symposium held January 1-6 in Big Sky, Montana on Angiogenesis and Lymphangiogenesis in Cancer, and Dr. William Garland, the Company's CEO, presented at the PepTalk meeting held January 11-16 in San Diego, California.

Besides AGX51, both speakers also touted the continually emerging importance of Id in the development and progression of cancer and the therapeutic potential of the novel, anti-Id oligonucleotides invented by Dr. Benezra. An initial report on one of these oligonucleotides (AGX1053) appeared last year in Nature Biotechnology 2008; 26: 91-100.

AngioGenex is currently pursuing the preclinical development of its small, patented molecules and oligonucleotides that have potent anti-angiogenic / anti-tumor activity through inhibition of the action of the Id proteins. The Chairman of the Board of AngioGenex, Dr. Richard Salvador, commented that "information accruing on the control of new blood vessel formation into tumors by the Id genes and proteins confirms that drugs that inhibit their activity, such as AGX1053 and AGX51, are the first in a class of new and unique anti-tumor agents. With sufficient funding we plan to have both drugs in man in 9 to 12 months. Our technology offers a potentially more effective and, therefore, a more cost effective anti-angiogenic based therapy for cancer tha
'/>"/>

SOURCE AngioGenex Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. William Garland Joins AngioGenexs New Board of Directors
2. AngioGenex Appoints New CEO to Direct Development of Anti-Cancer Drugs
3. AngioGenex Reviews 2008 Achievements and Sets Goals for 2009
4. Lexicon Presents Class of Compounds Modulating TPH1, the Target for its LX1031 Investigational Drug for Irritable Bowel Syndrome
5. Touching 418 Billion Lives, Hepatitis Still Presents Significant Threat to Global Health
6. Touching 418 Million Lives, Hepatitis Still Presents Significant Threat to Global Health
7. Nektar Presents Positive Results from Phase 1 Clinical Trial of NKTR-118 (oral PEG-naloxol) at American College of Clinical Pharmacology Meeting
8. Sangamo BioSciences Presents Data Demonstrating In Vivo Protection Against HIV Infection by CCR5-ZFN Therapeutic
9. Arpida Presents Preclinical and Clinical Data on Iclaprim at ICAAC
10. Arpida Presents Preclinical Data on AR-2474 at ICAAC
11. Resverlogix Presents Key Apo-Al/HDL Scientific Data at DALM

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)... Ambassador to also Visit Detroit , ...David Appia, French Ambassador for International I...rance Agency, , , , ,What: Ambassador Appia is av...usiness initiatives adopted by France to further d...e for innovation and development., , ,When: Availa...
(Date:11/24/2009)... Nov. 24 Sigma-Aldrich C...the NASDAQ OMX conference on Tuesday, December 1st...ted parties may listen via live audio broadcast ov....sig m a a ldrich.com/ . Users can click the...ut Sigma-Aldrich: Sigma-Aldrich is a leading Lif...
(Date:11/24/2009)...GHAI, Nov. 24 /PRNewswire-Asia/ -- Shanghai Biolax...nistration (SFDA) has approved the,investigational...roject,(Nodlin), an innovative insulin formulation...xy to initiate its first phase I clinical study. ,... high blood glucose and poor,metabolism. The compl...
(Date:11/24/2009)...November 24 Shire plc (L...opharmaceutical company, today,announced that it h...y for,velaglucerase alfa, the company,s enzyme rep...of Type 1 Gaucher disease. This is the third marke...een submitted, with previous,submissions in the Un...
Breaking Biology Technology:Biolaxy Secures IND Approval for Oral Insulin 2Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 2Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 3Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 4
...stics,Inc. (OTC Bulletin Board: BOVD) ("Boveran") ...t ("LOI") to acquire majority interest in Sophora,...ology lab ("Sophora")., Pursuant to the LOI, Dr. ...he Company,s Chief Pathologist and Director of Lab... lab services., Sophora is Boveran,s first planne...
...are Simplifies Medicare - For Free, MAYNARD, Mass...atest release of their PlanPrescriber tool. Medica... worry about whether they are,getting the most out...er,the brainchild of MIT Professor Glen Urban, pro...seniors quickly find their best Medicare insurance...
...erations, NAPLES, Fla., Sept. 8 Algenol Biofuels...vanced third generation biofuels,technology, today...as Chief,Science Officer. Dr. Coleman, currently t... the University of Toronto, has over 20 years of,e...iochemistry of,photosynthetic carbon metabolism in...
Other Biology Technology:Boveran Diagnostics, Inc. Announces Planned Acquisition of New York-Based Pathology Lab: Sophora Diagnostic Lab, Inc. 2On-Line Medicare Advisor Saves Seniors Time, Hassle and Money 2Algenol Biofuels Appoints Chief Science Officer 2
(Date:11/25/2009)...the California Institute of Technology (Caltech) h... behavior in the fruit fly, Drosophila melanogast...the relationship between the neurotransmitter dopa...(ADHD), are described in the December issue of the...ains only about 20,000 neurons and has long been c...
(Date:11/25/2009)...ve easy lives. In addition to mammalian immune sys...ies called bacteriophages, viruses that kill half ...bacteria and another class of microorganisms calle...s such as deep-sea volcanic vents) manage just fin... defense system that helps protect them from many ...
(Date:11/25/2009)...he Cell Death Research Laboratory in the Universit...ed the prestigious Johnson & Johnson Focused Fundi...rain cell damage in Parkinson,s disease. The award...ort of innovation and excellence in science, was a... this month at an event at the Hyatt Regency Hotel...
Breaking Biology News(10 mins):Caltech scientists find emotion-like behaviors, regulated by dopamine, in fruit flies 2Caltech scientists find emotion-like behaviors, regulated by dopamine, in fruit flies 3Caltech scientists find emotion-like behaviors, regulated by dopamine, in fruit flies 4Researchers discover biological basis of 'bacterial immune system' 2Researchers discover biological basis of 'bacterial immune system' 3Johnson & Johnson award goes to research of the cause of brain cell damage in Parkinson's 2American Oriental Bioengineering Announces Change in Independent Auditor 13494 1For Macho Men Doctor Visits Are Less Likely 54168 1For Macho Men Doctor Visits Are Less Likely 54168 2Vion Pharmaceuticals Reports 2009 Second Quarter And Six Month Results 54163 1Vion Pharmaceuticals Reports 2009 Second Quarter And Six Month Results 54163 2Vion Pharmaceuticals Reports 2009 Second Quarter And Six Month Results 54163 3Vion Pharmaceuticals Reports 2009 Second Quarter And Six Month Results 54163 4Vion Pharmaceuticals Reports 2009 Second Quarter And Six Month Results 54163 5Vion Pharmaceuticals Reports 2009 Second Quarter And Six Month Results 54163 6
...is release is also available in French . , Mon...ied what may be a pivotal first step towards the r...njury, using the bodys own stem cells. , This s...of the National Academy of Science, identifies key...critical information that could lead to novel ther...
...entists at John Carroll University, working in its... affordable accessory that appears to reduce the s...n shown to improve sleep patterns among people who... researchers have created glasses designed to bloc...an rhythm, which leads to improvement in ADHD symp...
...kville, Md., November 12, 2007 On September 10, 2...t several multivitamin supplements did not contain...s, B-50 Tablets, manufactured by IVC, Industries, ... Supplement Verification Program and carries the U...tudied the verified product to confirm the announc...
Other Biology News:Researchers take first steps towards spinal cord reconstruction following injury 2Market testing of dietary supplements and drugs underscores value of USP's public health programs 2
PG 3000 Photographic Digital Printer from FUJIFILM Life Science
...se Cytokine Array is a multiplex sandwich ELISA (e...tive measurement of 12 cytokines in serum; EDTA, h...ants. Each well of the microplate provided is spot...s in standards and samples added to the plate. Aft...
... fast and simple integration of FRT-sites into lar...tion of transgenic mouse models). The included FRT...mycin / kanamycin selection in prokaryotic and euk...(gb2) for expression of kanamycin resistance in E...
Agencourt AMPure 60ml Kit from Agencourt Bioscience
Biology Products: